Braveheart Bio, Inc.
BRVE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002131524
In the last 90 days, Braveheart Bio, Inc. insiders filed 9 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $124.1M in total
- 9
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BRVE, Q2 2026
No superinvestor reported holding BRVE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Braveheart Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 (view filing)5:53 PM ET | Aug 7 | 4 days | Andreessen Marc L and 3 others10% Owner | PPurchase | +1.10M | $18.00 | +$19.8M | +12.0%10.2M after | |
| Aug 11, 2026 (view filing)5:31 PM ET | Aug 7 | 4 days | Chimovits ErezDirector, 10% Owner | PPurchase | +1.94M | $18.00 | +$34.9M | New position273.3K after | 2 lotsDuplicate filing |
| Aug 11, 2026 (view filing)5:27 PM ET | Aug 7 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.94M | $18.00 | +$34.9M | New position273.3K after | 2 lots |
| Aug 7, 2026 (view filing)5:25 PM ET | Aug 7 | Same day | Forbion Growth III Management B.V. and 3 others10% Owner | PPurchase | +1.92M | $18.00 | +$34.6M | +19.8%11.6M after | |
| Aug 7, 2026 (view filing)5:25 PM ET | Aug 7 | Same day | Forbion Growth III Management B.V. and 3 others10% Owner | PPurchase | +1.68M | $18.00 | +$30.2M | +19.8%10.2M after | |
| Aug 7, 2026 (view filing)4:41 PM ET | Aug 7 | Same day | Rickey James PaulChief Financial Officer | PPurchase | +27.8K | $18.00 | +$500.0K | +5.6%520.9K after | |
| Aug 7, 2026 (view filing)4:31 PM ET | Aug 7 | Same day | Viehbacher ChristopherDirector | PPurchase | +83.3K | $18.00 | +$1.50M | +15.8%609.5K after | |
| Aug 7, 2026 (view filing)4:31 PM ET | Aug 7 | Same day | Malek David IDirector | PPurchase | +4.17K | $18.00 | +$75.0K | +0.8%533.8K after | |
| Aug 7, 2026 (view filing)4:30 PM ET | Aug 7 | Same day | Anderson Michele A.Chief Development Officer | PPurchase | +1.11K | $18.00 | +$20.0K | +0.3%332.2K after | |
| Aug 7, 2026 (view filing)4:30 PM ET | Aug 7 | Same day | Murdoch TravisCEO and President | PPurchase | +83.3K | $18.00 | +$1.50M | +2.9%2.94M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Braveheart Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding BRVE in 13F filings for Q2 2026.